
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Remove Complementary medicines filter Complementary medicines (7)
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Remove Prescription medicines filter Prescription medicines (5)
- Scheduling (55) Apply Scheduling filter
- Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA) (2)
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Therapeutic Goods Administration (TGA) filter Therapeutic Goods Administration (TGA)
- (-) Remove Complementary medicines filter Complementary medicines
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Prescription medicines filter Prescription medicines
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Prescription strong (Schedule 8) opioid use and misuse in Australia – options for a regulatory response
Closed on 2 March 2018
Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Closed on 12 January 2018
TGA communications and consultation processes: Online survey 2009
Closed on 21 June 2009